Prime appoints Megan Pollack as VP, Prime Aventine to drive payer access and evidence initiatives across the US

Based in the US, Megan brings extensive experience in payer access and value communications within the US healthcare landscape, along with clinical pharmacy expertise—offering a unique perspective to Prime Aventine, the US market access arm of Prime.

Prior to joining Prime Aventine, Megan served as director of US medical and value communications, for 9 years. She was responsible for the delivery and oversight of US value communications, including AMCP dossiers, pre-approval information exchange, and CMS Inflation Reduction Act response documents.

With a Doctorate of Pharmacy from the University of Florida and residencies in both general pharmacy and hematology/oncology at Vanderbilt University Medical Center, Megan brings a wealth of clinical and scientific expertise to the team. She is a Board Certified Oncology Pharmacist with clinical experience in both hematology and solid tumors and has 5 years’ experience in laboratory bench research, focused predominantly in the molecular biology of solid tumors.

Megan’s direct experience in clinical pharmacy and laboratory bench research gives her unique insight into the full drug development process, from product development to post-approval market access and clinical use.

Reflecting on her new role at Prime Aventine, Megan said “I am very excited to be joining the brilliant Prime team at such a pivotal time for US market access. I am looking forward to partnering with pharmaceutical and device manufacturers to shape innovative access strategies and drive impactful outcomes that will benefit patients and the wider industry.”

Sue O’Leary, Global EVP, Evidence & Access, shared of this new appointment “With external policies so linked, having a US payer expert as part of the global market access leadership team is essential to ensure we provide clients with the best payer lens across regions, and with Megan’s understanding of the landscape and what is shaping formulary decisions across the US we couldn’t be more thrilled to have her on board!”

This is a significant step in Prime’s continued growth and commitment to expanding our market access services in the US and Megan’s expertise will be invaluable as we continue to build and evolve our capabilities in this important area.

Welcome to Prime’s leadership team Megan!